ddn Online

The Blog of Drug Discovery News

Genzyme vs. sanofi-aventis: Who’s asking for too much?

We’ve run several stories on the developments around sanofi-aventis’ bid for Genzyme, from the intial overture and refusal to a potential suitor backing off to some interesting cuts and sales by Genzyme in the midst of all this.

All in all, it’s been quite a ride, and it gave the entire ddn staff flop sweats as we went to press with the September issue wondering just what might happen last-minute to nullify our coverage up to that point. Thank goodness for our online presence to keep up, eh?

In any case, with all that’s happened thus far, we thought we’d ask all of you what you think of the value of Genzyme in this potential merger or perhaps even hostile takeover.

Advertisements

September 13, 2010 - Posted by | Corporate, M&A activity | , , ,

No comments yet.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: